273 related articles for article (PubMed ID: 9413228)
1. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
2. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
[TBL] [Abstract][Full Text] [Related]
4. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
6. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
8. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
Katschinski DM; Robins HI
Int J Cancer; 1999 Jan; 80(1):104-9. PubMed ID: 9935239
[TBL] [Abstract][Full Text] [Related]
12. [Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
Noshuyo Byori; 1994; 11(1):59-64. PubMed ID: 8162152
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
[TBL] [Abstract][Full Text] [Related]
15. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
16. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
17. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
Aiba K; Funakoshi S; Mizunuma N; Dobashi N; Hirano A; Sano M; Kuraishi Y; Kamada M; Ohno N; Sugimoto Y
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1601-6. PubMed ID: 8060134
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
